An indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory mRCC patients. Background: There are currently three licensed first-line metastatic renal cell carcinoma (mRCC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback